抗抑郁药
抗焦虑药
耐受性
医学
药理学
敌手
5-羟色胺能
氟马西尼
焦虑
苯二氮卓
开阔地
麻醉
内科学
不利影响
精神科
血清素
受体
作者
Ianca Gontijo Cavalcante Santana,Lorena de Souza Almeida,Lorrane Kelle da Silva Moreira,Flávio Silva de Carvalho,Ricardo Menegatti,André Luís Batista da Rocha,Thais Aline Mazurok,Boniek G. Vaz,Luciano Morais Lião,Adriane Ferreira de Brito,James Oluwagbamigbe Fajemiroye,Élson Alves Costa,Pablinny Moreira Galdino
标识
DOI:10.1139/cjpp-2021-0729
摘要
Anxiety and depression are common mental disorders affecting millions of people worldwide. Unsatisfactory clinical outcomes with the use of the available pharmacological interventions among some patients demand newer drugs with proven efficacy, safety, and tolerability profile. In this study, the LQFM211, LQFM213, and LQFM214 were designed from the piperazine scaffold and administered orally in mice. These mice were later evaluated in the open field, elevated plus maze, and forced swimming tests to assess the exploratory, anxiolytic, and antidepressant-like activities, respectively. The mechanism of action of these new derivatives was evaluated using flumazenil (benzodiazepine antagonist) and WAY100635 (5-HT1A receptor antagonist). Unlike LQFM214, the LQFM211 and LQFM213 elicited anxiolytic and antidepressant-like effects. The blockade of the effect of LQFM213 by WAY100635 suggests the involvement of the serotonergic pathway.
科研通智能强力驱动
Strongly Powered by AbleSci AI